Lineage Cell Therapeutics, Inc. Increase (Decrease) Due from Affiliates
Lineage Cell Therapeutics, Inc. (LCTX) reported Increase (Decrease) Due from Affiliates of -$7.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseDueFromAffiliates · last filed 2022-03-10
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for the quarter ending 2020-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for the quarter ending 2020-03-31 was $40.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for the quarter ending 2019-12-31 was -$157.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for the quarter ending 2019-09-30 was $237.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for fiscal 2020 was -$7.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for fiscal 2019 was -$2.10M.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for fiscal 2018 was -$559.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) due from affiliates for fiscal 2017 was -$1.16M.
| Period end | Increase (Decrease) Due from Affiliates 3 month | Increase (Decrease) Due from Affiliates 3 month as first filed | Increase (Decrease) Due from Affiliates 6 month | Increase (Decrease) Due from Affiliates 9 month | Increase (Decrease) Due from Affiliates 12 month | Increase (Decrease) Due from Affiliates 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$7.00K 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | -$7.00K 10-Q · filed 2020-11-04 | |||||
| 2020-03-31 | $40.00K 10-Q · filed 2021-05-13 | -$117.00K derived: sum of 2 quarters · filed 2021-05-13 | $120.00K derived: sum of 3 quarters · filed 2021-05-13 | $64.00K derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $80.00K derived: sum of 2 quarters · filed 2021-03-11 | $24.00K derived: sum of 3 quarters · filed 2021-03-11 | -$2.10M 10-K · filed 2021-03-11 | ||
| 2019-09-30 | $237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $181.00K derived: sum of 2 quarters · filed 2020-11-04 | -$1.95M 10-Q · filed 2020-11-04 | -$2.02M derived: sum of 4 quarters · filed 2020-11-04 | ||
| 2019-06-30 | -$56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$2.19M 10-Q · filed 2020-08-06 | -$2.26M derived: sum of 3 quarters · filed 2020-08-06 | -$2.56M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | -$2.13M 10-Q · filed 2020-05-07 | -$2.20M derived: sum of 2 quarters · filed 2020-05-07 | -$2.51M derived: sum of 3 quarters · filed 2020-05-07 | -$2.51M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$379.00K derived: sum of 2 quarters · filed 2020-03-12 | -$384.00K derived: sum of 3 quarters · filed 2020-03-12 | -$559.00K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | -$306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$311.00K derived: sum of 2 quarters · filed 2019-11-12 | -$486.00K 10-Q · filed 2019-11-12 | -$883.00K derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$180.00K 10-Q · filed 2019-08-08 | -$577.00K derived: sum of 3 quarters · filed 2019-08-08 | -$1.00M derived: sum of 4 quarters · filed 2019-08-08 | ||
| 2018-03-31 | -$175.00K 10-Q · filed 2019-05-09 | $175.00K 10-Q · filed 2018-05-10 | -$572.00K derived: sum of 2 quarters · filed 2019-05-09 | -$1.00M derived: sum of 3 quarters · filed 2019-05-09 | -$1.56M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$397.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$825.00K derived: sum of 2 quarters · filed 2019-03-14 | -$1.39M derived: sum of 3 quarters · filed 2019-03-14 | -$1.16M 10-K · filed 2019-03-14 | $1.16M 10-K · filed 2018-03-15 | |
| 2017-09-30 | -$428.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$991.00K derived: sum of 2 quarters · filed 2018-11-08 | -$760.00K 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | -$563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$332.00K 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | $231.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |